MYGN logo

MYGNMyriad Genetics, Inc.

$4.25
$0.07
(1.62%)
Today
Closed $4.25
$0.00
(0.00%)
After Hours
Updated: 05:41 PM EDT
EarningsAug 4
Mkt Cap$408.02M
Vol1.27M
News
all
press releases
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Zacks
News Placeholder
More News
News Placeholder
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Zacks
News Placeholder
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Zacks
News Placeholder
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Zacks
News Placeholder
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Zacks
News Placeholder
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
News Placeholder
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock...
Yahoo! Finance: News
News Placeholder
TD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00
TD Cowen decreased their target price on Myriad Genetics from $7.00 to $6.00 and set a "hold" rating for the company in a research note on Wednesday...
MarketBeat
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Given New $5.50 Price Target at Wells Fargo & Company
Wells Fargo & Company dropped their target price on Myriad Genetics from $6.00 to $5.50 and set an "equal weight" rating for the company in a report on Wednesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.